The Birth of Pharmacognosy

The word nobody can pronounce , and why it matters

Pharma-cog-nosy. Four syllables, one deeply unfashionable discipline, and arguably the intellectual ancestor of every cannabinoid, terpene, and peptide article on this site. I'll admit I got the pronunciation wrong for years. "Pharmacognosis" is how I said it until a pharmacist in a Hobart continuing-education session politely corrected me in front of about sixty people. Anyway.

The short version is this: pharmacognosy is the scientific study of drugs derived from natural sources , plants, fungi, animals, minerals. Not the pharmacology of what those compounds do inside a body, but the prior question: what are they, where do they come from, how do we identify and characterise them? It sits at the junction of botany, chemistry, and what we'd now call ethnobiology, and it has been quietly running in the background of medicine for roughly two thousand years before anyone gave it a name.

Where the tradition actually begins

The standard origin story starts with Pedanius Dioscorides, a Greek physician working in the first century CE who compiled De Materia Medica , a five-volume catalogue of around six hundred plants, along with minerals and animal products, documenting their properties, preparation, and uses. It circulated in manuscript form for fifteen centuries. Fifteen. A pharmacopoeia with a longer shelf life than most countries.

But Dioscorides wasn't working from nothing. He was drawing on Egyptian papyri, Babylonian clay tablets, and centuries of accumulated Greco-Roman trade knowledge. The Ebers Papyrus, dating to roughly 1550 BCE, already described hundreds of plant-based preparations. What Dioscorides did was systematic: he organised, cross-referenced, and; critically, tried to separate observed properties from the more mythological attributions that had accumulated around certain plants.

This tension between systematic observation and inherited belief is one I find genuinely fascinating, because it never fully resolves. We still deal with versions of it every time a new compound gets picked up by wellness marketing before the peer review is in.

The naming of the discipline, Seydler, 1815

The word "pharmacognosy" is attributed to Johann Adam Schmidt (some sources credit C.A. Seydler's 1815 work Analecta Pharmacognostica as the first formal use in print). Either way, early nineteenth century, German-speaking Europe, the tail end of the Enlightenment. Chemistry was maturing. Linnaean taxonomy had given botanists a shared vocabulary. Microscopy was improving. The conditions were right for someone to say: we need a word for this specific thing; the systematic study of the origin, distribution, and raw characterisation of natural drug substances.

What followed was about a century of intensive plant prospecting. European colonial networks, and I won't gloss over the extractive politics of this, gave Western scientists access to plant knowledge that indigenous communities had developed over generations across South America, Asia, Africa, and Australia. Quinine from cinchona bark. Morphine isolated from opium poppy resin in 1804 by Friedrich Sertürner. Salicin from willow bark, which eventually became aspirin. The nineteenth century was, pharmacognostically speaking, extraordinarily productive. And almost none of the knowledge origination was credited to its actual sources.

The twentieth century pivot: isolation over the whole plant

Here's where the intellectual history gets a bit more contested. From roughly the 1920s onward, the dominant logic in pharmaceutical development shifted from characterising whole-plant materials to isolating, synthesising, and patenting single active compounds. Pharmacognosy departments at universities were quietly defunded or absorbed into pharmacology. The discipline was seen as old-fashioned; a bit like a pre-scientific hold-over.

In my view, this was too clean a break, and we're still unwinding the consequences. The reductive assumption, one compound, one target, one effect, turned out to be a significant oversimplification for many natural product classes. The concept of the entourage effect, whatever its current evidentiary status, is partly a response to that overcorrection. So is the renewed interest in full-spectrum versus isolate formulations. These aren't fringe ideas; they're the field partially re-asking questions it dismissed in the mid-twentieth century.

Pharmacognosy never disappeared entirely. It kept going in research settings, particularly in natural products chemistry and the search for novel lead compounds for drug development. Roughly half of all FDA-approved drugs between 1981 and 2019, per a widely cited analysis by Newman and Cragg published in the Journal of Natural Products, were derived from or inspired by natural product chemistry. The discipline just got rebranded as "natural products chemistry" in a lot of places.

Plant medicine and the long road to phytomedicine

The modern framing of phytomedicine; standardised, quality-controlled preparations from plant sources, is in many ways pharmacognosy's direct descendant. The key conceptual shift was from "this plant does X" to "this plant contains compounds A, B, and C, present in these concentrations, with these measurable properties." That shift requires standardised extracts, defined analytical methods, and the kind of rigorous sourcing and identity verification that pharmacognosy was built around.

It's also where regulatory frameworks come in. In Australia, the Therapeutic Goods Administration (TGA) applies a tiered system to plant-based medicines that depends heavily on the quality of the starting material, species identification, part of plant used, extraction method, concentration of markers. A listed medicine on the Australian Register of Therapeutic Goods (ARTG) must meet these standards. The pharmacognostic work; verifying what you've actually got, is foundational to that entire process.

Cannabinoids: a case study in belated pharmacognosy

Cannabis is an interesting case study here, because the pharmacognosy lagged the ethnobotany by centuries. The plant's traditional use across Central Asia, the Middle East, and India is documented going back well over two thousand years. But the systematic chemical characterisation didn't really begin until the mid-twentieth century. Raphael Mechoulam and his colleagues at the Hebrew University of Jerusalem isolated and described the structure of tetrahydrocannabinol (THC) in 1964, and cannabidiol (CBD) had been isolated earlier, in 1940, though its structure wasn't confirmed until 1963.

What followed was the gradual mapping of the plant's chemistry, dozens of cannabinoids including cannabigerol (CBG), various terpenes including well-characterised compounds like beta-caryophyllene and linalool, and the later discovery of the endocannabinoid system in the early 1990s, which gave researchers a mechanistic framework for asking how plant cannabinoids interact with mammalian physiology in the first place.

I was reading the Mechoulam group's early papers last winter, between morning swims; the water was about 11 degrees, so I had plenty of motivation to get back inside and sit with something absorbing. What struck me is how explicitly pharmacognostic the early work was. Careful botanical sourcing, rigorous extraction, methodical chemical characterisation before any biological questions were even posed. The sequence matters. You can't meaningfully study what a compound does if you haven't first established with confidence what compound you're actually looking at.

What modern pharmacognosy looks like

Today the discipline encompasses molecular identification techniques, metabolomics, and computational approaches to mapping the chemistry of natural product libraries. But the core intellectual task remains the same one Dioscorides was wrestling with: accurate identification, rigorous characterisation, and honest documentation of what we know versus what we're inferring.

That last part is where I think the field, and the broader conversation about plant-based medicine, still has hard yards ahead. The history is full of moments where preliminary characterisation got ahead of established evidence; where a compound's presence in a plant was taken as sufficient reason to make claims that the clinical research hadn't yet supported. Pharmacognosy at its best is a discipline of precision and restraint. It tells you what you have. What you do with that information is a separate question, and one that deserves equally careful handling.

Understanding how to read that chain of evidence; from botanical source to extracted compound to biological characterisation to clinical data, is exactly the kind of literacy that makes everything else on this site more useful.

Sources

• Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019, Journal of Natural Products (NCBI/NIH)
• Complementary medicines regulation; Therapeutic Goods Administration (TGA)
• Mechoulam R, Gaoni Y. A Total Synthesis of dl-Δ1-Tetrahydrocannabinol, the Active Constituent of Hashish, NCBI/NIH
• WHO guidelines on good herbal processing practices for herbal medicines, World Health Organization

, Hannah Bui, Evidence & research-literacy writer